In vitro evaluation of combination chemotherapy against human tumor cells (Review)

Oncology Reports

Volumn 5, Issue 5, 1998, Pages 1035-1042

  Fan, Weimin ^a   Johnson, Korey R ^a   Miller III, Merrill C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

5 fluorouracil; Apoptosis; Cell cycle arrest; Combination chemotherapy; In vitro evaluation; Paclitaxel

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; FLUOROURACIL;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CLONOGENIC ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

EID: 0031876631     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.5.1035     Document Type: Review

References (92)

1. De Vita VT: Principles of chemotherapy. In: Cancer: Principles and Practice of Oncology. 4th edition. DeVita VT, Hellman S and Rosenberg SA (eds.) JB Lippincott Company, Philadelphia, pp27 6-292, 1993.
2. Sartorelli AC: Some approaches to the therapeutic exploitation of metabolic sites of vulnerability of neoplastic cells. Cancer Res 29: 1019-1032, 1969.
3. Frei E III: Combination cancer therapy: presidential address. Cancer Res 32: 2593-2607, 1972.
4. Frei E III: Clinical studies of combination chemotherapy for cancer. In: Synergism and Antagonism in Chemotherapy. Chou T-C and Rideout DC (eds.) Academic Press, San Diego, pp103-108, 1991.
5. Yarbro JW: The scientific basis of cancer chemotherapy In: The Chemotherapy Source Book. 2nd edition. Perry MC (ed.). Williams and Wilkins, Baltimore, pp1-18, 1996.
6. Rideout DC and Chou T-C: Synergism, antagonism and potentiation in chemotherapy: an overview. In: Synergism and Antagonism in Chemotherapy. Chou T-C and Rideout DC (eds.) Academic Press, San Diego, pp3-60, 1991.
7. Bertino JR and Chou T-C: Chemotherapy: Synergism and antagonism. In: Encyclopedia of Cancer. Vol. 1. Bertino JR (ed.) Academic Press, San Diego, pp368-379, 1997.
8. Sevin B-U, Ferras JP, Averette HE, Donato DM and Penal ver M: Chemosensitivity testing in ovarian cancer. Cancer Suppl 71: 1613-1620, 1993.
9. Csoka K, Liliemark J, Larsson R and Hygren P: Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with matologic or solid tumors. Semin Oncol 22 (Suppl. 11): 47-53, 1995.
10. Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M and Wittes RE: Clinical drug development: an analysis of phase II trials, 1970-1985. Cancer Treat Rep 71: 71-80, 1987.
11. Weisenthal LM: Predictive assays for drug and radiation resistance. In: Human Cancer in Primary Culture, a Handbook. Masters JM (ed.) Kluwer Academic Publishers, Dordrecht, pp103-148, 1991.
12. Shaw GL, Gazdar AF, Phelps R, Steinberg SM, Linnoila RI, Johnson BE, Oie HK, Russel EK, Ghosh BC, Pass HI, Minna JD, Mulshine JL and Ihde DC: Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem (Suppl. 24): 173-185, 1996.
13. Larsson R, Fridborg H, Kristensen J, Sundström C and Nygren P: In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA). Br J Cancer 67: 969-974, 1993.
14. Johnson KR, Wang L, Miller III MC, Willingham MC and Fan W: 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin Cancer Res 3: 1739-1745, 1997.
15. Selby P, Buick RN and Tannock I: A critical appraisal of the human tumor stem-cell assay. JAMA 308: 129-134, 1983.
16. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS and Moon TE: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Eng J Med 298: 1321-1237, 1978.
17. Salmon SE, Alberts DS, Durie BG, Meyskens FL, Jones SE, Soehnlen B, Chen HS and Moon T: Clinical correlations of drug sensitivity in the human tumor stem cell assay. Rec Res Cancer Res 74: 300-305, 1980.
18. Von Hoff DD, Cowan J, Jarris F and Reisdorf G: Human tumor cloning: feasibility and clinical correlations. Cancer Chemother Pharmacol 6: 265-271, 1981.
19. Sondak VK, Korn EL and Kern DH: In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. Int J Cell Cloning 6: 378-391, 1988.
20. Shoemaker RH, Wolpert-DeFilippes MK, Kern DH, Lieber MM, Makuch RW, Melnick NR, Miller WT, Salmon SE, Simon RM, Venditti JM and von Hoff DD: Application of a human tumor colony-forming assay to new drug screening. Cancer Res 45: 2145-2153, 1985.
21. 3H]thymidine incorporation in a modified human tumor stem cell assay. Cancer Res 42: 4683-4689, 1982.
22. Sondak VK, Korn EL and Kern DH: In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. Int J Cell Cloning 6: 378-391, 1988.
23. Rotman B, Teplitz C, Dickinson K and Cozzonlino JP: Individual human tumors in short-term micro-organ cultures: chemosensitivity testing by fluorescent cytoprinting. In Vitro Cell Dev Biol 24: 1137-1146, 1988.
24. Untch M, Sevin B-U, Perras JP, Angioli R, Untch A, Hightower RD, Koechli O and Averette HE: Evaluation of paclitaxel (Taxol), cisplatin and the combination paclitaxelcisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol 53: 44-49, 1994.
25. Hightower RD, Sevin B-U, Perras JP, Untch M, Angioli R, Ramos B and Averette H: Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay. Gynecol Oncol 47: 186-190, 1992.
26. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
27. Kratzke RA and Kramer BS: Evaluation of in vitro chemosensitivity using human lung cancer cell lines. J Cell Biochem (Suppl. 24): 160-164, 1996.
28. Slater TF, Sawyer B and Strauli U: Studies on succinatetetrazolium reductase systems. III. Points of coupling of four different tetrazolium salts. Biochim Biophys Acta 77: 383-393, 1963.
29. Holst-Hansen C and Brünner N; MTT-cell proliferation assay. In: Cell Biology: a Laboratory Handbook. Vol. I. 2nd edition. Celis JE (ed.) Academic Press, San Diego, pp16-18, 1998.
30. Klaassen U, Harstrick A, Scheleucher N, Vanhoefer U, Schröder J, Wilke H and Seeber S: Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxyifosfamide in cisplatin-sensitive and-refractory human ovarian carcinoma cell lines. Br J Cancer 74: 224-228, 1996.
31. Paul DM, Garrett AM, Meshad M, DeVore RD, Porter LL and Johnson DH: Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience. Semin Oncol 23 (Suppl. 1): 48-52, 1996.
32. Klaassen U, Wilke H, Pari CP, Strumberg D, Harstrick A, Eberhardt W, Becher R, Diergarten K and Seeber S: Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis. Semin Oncol 22 (Suppl. 14): 7-11, 1995.
33. Yokes EE, Stupp R, Haraf D, Moran W, Malone D, Wenig B, Sweeney P and Weichselbaum RR: Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil and concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol 22 (Suppl. 6): 47-52, 1995.
34. Ajani JA, Ilson DH and Kelsen DP: The activity of paclitaxel in gastrointestinal tumors. Semin Oncol 22 (Suppl. 12): 46-53, 1995.
35. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y and Adachi KI: Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74: 704-710, 1996.
36. Komp DM and Cox BJ: Cytocentrifugation in the management of central nervous system leukemia. J Pediatr 81: 992-994, 1972.
37. Juan G and Darzynkiewicz Z: Cell cycle analysis by flow and laser scanning cytometry. In: Cell Biology, a Laboratory Handbook. Vol 1. 2nd edition. Celis JE (ed.) Academic Press, San Diego, pp261-274, 1998.
38. German AM, Samali A and McGowan AJ: Use of flow cytometry techniques in studying mechanism of apoptosis in leukemic cells. Cytometry 29: 97-105, 1997.
39. Crissman HA and Tobey RA: Cell cycle analysis in 29 minutes. Science 184: 1297-1298, 1974.
40. Darzynkiewicz Z, Gong J, Juan G, Ardelt B and Traganos F: Cytometry of cyclin proteins. Cytometry 25: 1-13, 1996.
41. Rabinovitch PS: DNA content histogram and cell cycle analysis. Methods Cell Biol 41: 364-387, 1994.
42. Wada Y, Kawamoto K, Oka S, Yamashita T, Kumazawa T and Matsumura H: Clinical evaluation for the mechanism of cisplatin with bromodeoxyuridine by flow cytometry and clinico-histological study. Life Sci 44: 259-264, 1989.
43. Kawamoto K, Herz F, Wolley RC, Hirano A, Kajikawa H and Koss LG: Flow cytometric analysis of the DNA distribution in human brain tumors. Acta Neuropathol 46: 39-44, 1979.
44. Kawamoto K, Kawakami K, Kawamura Y, Matsumura H and Ohyama A: New sensitivity test using flow cytometry. J Neurol Oncol 6: 361-370, 1988.
45. Kawamoto K, Wada Y, Kumazawa H, Yanashita T, Dumazawa T and Matsumura H: Experimental and clinical evaluation by flow cytometry for mechanisms of combination therapy (cisplatin and peplomycin). Cytometry 13: 307-313, 1992.
46. Dolbeare F, Gratzner H, Pallavicini M and Gray JW: Flow cytometric measurements of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 80: 5573-5577, 1983.
47. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
48. Ormerod MG: How cytometry of apoptotic cells. In: Cell Biology, a Laboratory Handbook. Vol I. 2nd edition. Celis JE (eds.) Academic Press, San Diego, pp351-356, 1998.
49. Juan G and Darzynkiewicz Z: In situ DNA stread break labeling for analysis of apoptosis and cell proliferation by flow and laser scanning cytometry. In: Cell Biology, a Laboratory Handbook. Vol I. 2nd edition. Celis JE (ed.) Academic Press, San Diego, pp341-356, 1998.
50. Miller MC, Johnson KR, Willingham MC and Fan W: Apoptotic cell death induced baccation III, a precursor of paclitaxel, may occur without G2/M arrest. Mol Pharmacol (In press).
51. Thatte U and Dahanukar S: Apoptosis: clinical relevance and pharmacological manipulation. Drugs 54: 511-532, 1997.
52. Feicher TA: Apoptosis. Ann Allergy Asthma Immunol 78: 245-249, 1997.
53. Waring P, Kos FJ and Mullbacher A: Apoptosis or programmed cell death. Med Res Rev 11: 219-236, 1991.
54. efc2 coincident with paclitaxel-induced apoptosis. Cell Growth Differ 5: 1041-1050, 1994.
55. Milross CG, Mason KA, Hunter NR, Chung W-K, Peters LJ and Milas L: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88: 1308-1314, 1996.
56. Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC and Peters LJ: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 35: 297-303, 1995.
57. Collins JA, Schandl CA, Young KK, Vesely J and Willingham MC: Major DNA fragmentation is a late event in apoptosis. J Histochem Cytochem 45: 923-934, 1997.
58. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1-16, 1997.
59. Tomei LD, Shapiro JP and Cope FO: Apoptosis in C3H/10T1/2 mouse embryonic cells: evidence for internucleosomal DNA modification in the absence of double-strand cleavase. Proc Natl Acad Sci USA 90: 853-857, 1993.
60. Fan W, Schandl CA, Cheng L, Norris JS and Willingham MC: Glucocorticoids modulate paclitaxel cytotoxicity in human solid tumor cells. Cell Pharmacol 3: 343-348, 1996.
61. Haldar S, Chintapalli J and Croce CM: Taxol-induced bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
62. Haldar S, Jena N and Croce CM: Inactivation of bcl-2 by phosphorylation and death of prostate cancer cells. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
63. Schandl CA, Priest DG and Willingham MC: Phosphorylation of bcl-2 is a cell cycle-regulated event. Cell Pharmacol 3: 367-372, 1996.
64. Halder S, Basu A and Croce CM: Serine 70 is one of the critical sites for drug-induced bcl2 phosphorylation in cancer cells. Cancer Res 58: 1609-1615, 1998.
65. Johnson KR, Miller MC and Fan W: Antagonistic interplay between anti-mitotic and G1/S arresting agents in experimental combination therapy. Proc Amer Assoc Cancer Res p507,1998.
66. Coley HM: Drug resistance studies using fresh human ovarian carcinoma and soft tissue sarcoma samples. Keio J Med 46: 142-147, 1997.
67. Wu-Wong J, Chiou WJ, Dickinson R and Opgenorth TJ: Endothelin attenuates apoptosis in human smooth muscle cells. Biochem J 328: 733-737, 1997.eeee
68. Brockhaus F and Brüne B: U937 apoptotic cell death by nitric oxide: bcl-2 downregulation and caspase activation. Exp Cell Res 238: 33-41, 1998.
69. cdc2 kinase. Cell Growth Differ 9: 23-29, 1998.
70. Cuvillier O, Rosenthal DS, Smulson ME and Spiegel S: Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas-and ceramide-mediated apoptosis in Jurkat T lymphocytes. J Biol Chem 273: 2910-2916, 1998.
71. Yuhas JM, Tarleton AE and Harman JG: In vitro analysis of the response of multicellular tumor spheroids exposed to chemotherapeutic agents in vitro or in vivo. Cancer Res 38: 3595-3598, 1978.
72. Frankel A, Buckman R and Kerbel RS: Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as mulicellular tumor spheroids. Cancer Res 57: 2388-2393, 1997.
73. Weisenthal LM, Dill PL, Kurnick NB and Lippman ME: Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res 43: 258-264, 1983.
74. Amos DB, Bashir H, Boyle W, MacQueen M and Tiilikainen A: A simple microcytotoxicity test. Transplantation 7: 220-223, 1969.
75. Duerst RE and Frantz CN: A sensitive assay of cytotoxicity applicable to mixed cell populations. J Immunol Methods 82: 39-46, 1985.
76. Weisenthal LM, Marsden JA, Dill PL and Macaluso CK: A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 43: 749-757, 1983.
77. Lichtenstein A, Kahle J and Bonavida B: Use of a self-generating percoll gradient and single cell cytotoxicity assay to identify tumor-lytic properties of inflammatory neutrophils. J Immunol Methods 81: 95-106, 1985.
78. Filman DJ, Brawn RJ and Dandliker WB: Intracellular supravital stain delocalization as an assay for antibody-dependent complement-mediated cell damage. J Immunol Methods 6: 189-207, 1975.
79. Heeg K, Reimann J, Kabelitz D, Hardt C and Wagner H: A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies. J Immunol Methods 77: 237-246, 1985.
80. Green LM, Reade JL and Ware CF: Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods 70: 257-268, 1984.
81. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D and Boyd MR: Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48: 4827-4833, 1988.
82. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D. Warren JR, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
83. Ruff MR and Gifford GE: Purification and physico-chemical characterization of rabbit tumor necrosis factor. J Immunol 125: 1671-1677, 1980.
84. Larsson R, Kristensen J, Sandberg C and Nygren P: Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50: 177-185, 1992.
85. Shirhatti V and Krishna G: A simple and sensitive method for monitoring drug-induced cell injury in cultured cells. Anal Biochem 147: 410-418, 1985.
86. Brunner KT, Mauel J, Cerottini JC and Chapuis B: Quantitative assay of the lytic action of immune lymphoid cells on 51-Crlabelled allogeneic target cells in vitro; inhibition by isoantibody and by drags. Immunology 14: 181-196, 1968.
87. Tolman KG, Peterson P, Gray P and Hammar SP: Hepatotoxicity of salicylates in monolayer cell cultures. Gastroenterology 74: 205-258, 1978.
88. Feutren G, Lacour B and Bach JF: Immune lysis of hepatocytes in culture: accurate detection by aspartate aminotransferase release measurement. J Immunol Methods 75: 85-94, 1984.
89. Cheng LR, Zheng S, Raghunathan K, Priest DG, Willingham MC, Norris JS and Fan W: Characterisations of taxol-induced apoptosis and altered gene expression in human breast cancer cells. Cell Pharmacol 2: 249-257, 1995.
90. Fan W, Cheng LR, Norris JS and Willingham MC: Glucocorticoids selectively inhibit taxol-induced apoptosis in a human breast cancer cell line. Cell Pharmacol 3: 435-440, 1996.
91. Greco MR, Bravo G and Parsons JC: The search for synergy: A critical review from a response surface prospective. Phamacol Rev 47: 331-385, 1995.
92. Coley HM: Drug resistance studies using fresh human ovarian caricinoma and soft tissue sarcoma samples. Keio J Med 46: 142-147, 1997.